Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203937 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL193513 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| Ammonia Solution, Strong SCHEMBL10483782 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| Ammonia Solution, Strong SCHEMBL10483779 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL7105559 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL8058978 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL7360600 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL7766358 | 0.91 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL22829567 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL25594806 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100273-A1 | METHOD FOR PRODUCING USEFUL SUBSTANCE, CULTURE SOLUTION FOR CULTURING ALGAE, APPARATUS FOR PRODUCING USEFUL SUBSTANCE, AND ALGAE CONTAINING USEFUL SUBSTANCE | ＮＴＴ株式会社 | 2026-05-15 | — | — | WO | claimed |
| CN-121851107-B | Aromatic acid salt of apolipoprotein E mimic peptide, and preparation method and medical application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| CN-119679774-A | Medicine for preventing or treating metabolic diseases and application thereof | 北京体育大学 | 2025-03-25 | — | — | CN | claimed |
| CN-119592528-A | L-amino acid ligase and application thereof in catalytic synthesis of L-valine dipeptide and derivatives thereof | 上海合全药物研发有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119320777-A | Metabolite screening method for promoting expression of porcine intestinal defensin pBD1 and application thereof | 浙江大学 | 2025-01-17 | — | — | CN | claimed |
| CN-114269951-B | Diagnostic method for aesthetic deterioration of skin | 欧莱雅 | 2024-12-27 | — | — | CN | claimed |
| CN-119039213-A | Method for constructing tetra-substituted olefin by remote C (sp 3) -H bond biaryl | 广西科学院 | 2024-11-29 | — | — | CN | claimed |
| US-6743944-B1 | FORMING DIASTEREOMERIC SALT OF RACEMIC 4-AMINO-2-METHYL-BUTANE-1-OL AND OPTICALLY ACTIVE ORGANIC ACID; CRYSTALLI-ZATION; ALKALI SOLUTION DECOMPOSITION | MITSUBISHI RAYON CO., LTD. (JP) | 2004-06-01 | — | — | US | claimed |
| WO-2003022247-A1 | INJECTABLE COMPOSITION OF PACLITAXEL | CHOONGWAE PHARMA CORPORATION (KR) | 2003-03-20 | — | — | WO | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| US-6030823-A | FOR INDUSTRIAL PRODUCTION OF D-AMINO ACIDS FROM N-ACETYL-D-AMINO ACIDS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-02-29 | — | — | US | claimed |
| US-5212069-A | Forming dipeptides from amides and glycine, cysteine or methionine | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1993-05-18 | — | — | US | claimed |
| US-5134073-A | Culture product of zoogloea ramigera | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1992-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | SMN1; SMN2 2156/4885ALDH1A1 822/4885LMNA 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.